This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Fluviral S/F(GSK1536489A), FLU Q-QIV (GSK2282512A), Fluviral Quadrivalent
FluLaval (Fluviral, GSK1536489A) is the trivalent formulation, and FLU Q-QIV (GSK2282512A) is the quadrivalent.
FluLaval is marketed in Canada under the name Fluviral. It is an injectible influenza vaccine containing trivalent, inactivated split-viron prepared in eggs. The viral strains incorporated into the vaccine vary yearly depending on which the USPHS designates as mostly likely to be prevalent. FluLaval contains no adjuvant.
GlaxoSmithKline acquired Fluviral through its acquisition of ID Biomedical.
In September 2005, GlaxoSmithKline and ID Biomedical Corporation announced a definitive agreement for GSK to acquire ID Biomedical. In December 2005, ID Biomedical announced that the acquisition by GlaxoSmithKline closed and ID Biomedical is now a wholly-owned subsidiary of GSK.
Additional information available to subscribers only: